#United States #New York #Class Action #Geron Corporation #Rytelo

Overview of the Recent Legal Developments Concerning Geron Corporation

On May 12, 2025, a significant notice was issued by The Gross Law Firm, directed toward the shareholders of Geron Corporation (NASDAQ: GERN). This notice highlights the impending class action lawsuit that has important implications for investors who purchased shares during the designated class period, which runs from February 28, 2024, to February 25, 2025.

Class Actions and Their Importance

Class action lawsuits serve as a critical mechanism for investors who believe they have been wronged by misleading corporate actions or statements. They allow individuals to pool resources and seek legal redress collectively, which can often be a more effective approach than pursuing claims individually. For Geron shareholders, this represents a chance to hold the company accountable for alleged misrepresentations regarding its products and business strategies.

Allegations Against Geron Corporation

The core of the complaint stems from statements made by Geron’s management concerning Rytelo (imetelstat)—a drug that was expected to have a significant impact in its targeted market. Allegations suggest that the defendants provided positive insights about the launch and anticipated growth of Rytelo while intentionally downplaying critical risks associated with its marketing and regulatory conditions.

Key Points from the Allegations:

1. Optimistic Projections: Statements included a confident outlook on Geron’s ability to meet the unmet needs of patients and their projected commercial success.
2. Dismissal of Risks: There were claims that management downplayed various risks, such as the challenges related to mandatory monitoring requirements for Rytelo and existing competitive pressures in the sector.
3. Growth Decline: The situation escalated when Geron announced its financial results for the fourth quarter of the fiscal year 2024. The announcement revealed that the growth trajectory of Rytelo had stagnated, attributing this decline to seasonal factors, rising competition, and insufficient market awareness, which contradicted previous claims made by the company's executives.

Following the release of this information, Geron's stock price experienced a dramatic decrease, plummeting from $2.37 to $1.61 per share in just one day—a staggering drop of about 32.07%.

Call to Action for Shareholders

The Gross Law Firm strongly urges shareholders to consider joining the class action lawsuit. There is a specific deadline of May 12, 2025, by which shareholders must register if they wish to be considered for lead plaintiff status. However, taking action to participate in the recovery process does not require being appointed as a lead plaintiff.

Steps to Get Involved:

• - Registration: Shareholders who bought shares during the specified class period can register using the form provided by The Gross Law Firm.
• - Monitoring: By registering, shareholders will also be enrolled in a monitoring program that offers status updates throughout the lawsuit's duration, keeping them informed about developments and next steps.
• - No Cost: Participation in this case does not involve any costs or obligations for the shareholders.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its dedication to investor rights. The firm focuses on bringing justice to stakeholders who have faced negative outcomes due to fraudulent activities or misleading corporate disclosures. Their mission is not only to recover losses for shareholders but also to encourage companies to adhere to ethical standards and best practices in corporate governance.

Contact Information

Investors wishing to learn more about their options or to join the class action can contact The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

As the developments unfold, Geron shareholders are encouraged to stay alert and proactive in these proceedings to ensure their rights are adequately represented.